“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market,” claimed Aridor, chairman of the board of AEBi
New Delhi: Innovative research has fueled the development of new medications and treatment technologies but when it comes to cancer, a disease that has been spreading at a disturbing pace across the globe, no development or advancement has come to promising a cure for treating cancer completely.
However, an Israeli biotech company has recently claimed that it will finally come up with a a cure for cancer within a year.
Accelerated Evolution Biotechnologies Ltd (AEBi), founded in 2000 from the ITEK Weizmann technology incubator has made the bold claims to cure the disease completely. The astonishing claim immediately went viral on medical and social media across the world.
Dan Aridor from the company in an interview to the Jerusalem Post said, “We believe we will offer in a year’s time a complete cure for cancer. Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market.”
Aridor, chairman of the board of AEBi and CEO Dr. Ilan Morad, say their treatment, which they call MuTaTo (multi-target toxin) is essentially on the scale of a cancer antibiotic – a disruption technology of the highest order.
The potential treatment is called “MuTaTo,” or “multitarget toxin.” MuTaTo consists of peptides (short strands of amino acids) developed by the scientists that latch onto multiple sites on a cancer cell at once, according to the daily. By binding to multiple sites on a cancer cell, the treatment doesn’t give the cell enough time to mutate again before another peptide in the same mix, this one toxic to cancer cells, swoops in and eradicates cancer, the scientists claimed.
In addition, AEBi said that this cure will be effective from the first day and that the treatment will last a few weeks with no or few side effects, on the order of a “rush” or “less than a headache.” The company also told the daily that the treatment would cost less than the cancer treatments available today.
After successful mice trials, CEO of the biotech company Dr Ilan Morad claimed that they are now fast-tracking MuTaTo to conduct human trials through this year. He’s confident MuTaTo will perform as expected in humans as well — and be a 100% cancer cure that the world has been waiting for.
The claims immediately drew the attention of scientists all over the world, many of whom showed heavy doubts criticised and miffed the company’s claim. However, the company maintained that it currently “can’t afford” to publish the preliminary results